Alkaloids as a source of potential anticholinesterase inhibitors for the treatment of Alzheimer's disease

Journal of Pharmacy and Pharmacology

Volumn 65, Issue 12, 2013, Pages 1701-1725

  Konrath, Eduardo Luis ^a   Passos, Carolina Dos Santos ^a   Klein Júnior, Luiz Carlos ^a   Henriques, Amélia T ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

acetylcholinesterase inhibition; alkaloids; Alzheimer's disease; butyrylcholinesterase inhibition; plants

Indexed keywords

ACETYLCHOLINESTERASE; ALKALOID; AMYLOID PROTEIN; BUXABENZAMIDIENINE; BUXAKASHMIRAMINE; BUXAMIDINE; BUXAMINE B; BUXAMINE C; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; CHUANBEINONE; CONESSIMIN; EBEIEDINONE; EPIPACHYSAMINE D; GALANTAMINE; HOOKERIANAMIDE I; HUPERZINE A; INDOLE DERIVATIVE; ISOQUINOLINE DERIVATIVE; JULIFLORINE; MONOTERPENE DERIVATIVE; NATURAL PRODUCT; PEGANOLE; PHYSOSTIGMINE; QUINOLIZIDINE DERIVATIVE; SARACOCINE; SARCODINE; TRITERPENOID; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASICINE;

ALZHEIMER DISEASE; AMARYLLIDACEAE; AMINO ACID SEQUENCE; BUXACEAE; DRUG POTENCY; ENZYME ACTIVE SITE; ENZYME BINDING; ENZYME INHIBITION; HUMAN; LYCOPODIACEAE; MOLECULAR DOCKING; MOLECULAR MODEL; NONHUMAN; PREDICTION; REVIEW; STRUCTURE ACTIVITY RELATION;

ACETYLCHOLINESTERASE INHIBITION; ALKALOIDS; ALZHEIMER'S DISEASE; BUTYRYLCHOLINESTERASE INHIBITION; PLANTS;

ALKALOIDS; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; CHOLINESTERASE INHIBITORS; CHOLINESTERASES; HUMANS; ISOQUINOLINES; MOLECULAR DOCKING SIMULATION; MONOTERPENES; QUINOLIZIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; TAU PROTEINS; TRITERPENES;

EID: 84888013068     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/jphp.12090     Document Type: Review

References (156)

1. Cummings JL,. Alzheimer's disease. N Engl J Med 2004; 351: 56-67.
2. Brookmeyer R, et al. Forecasting the global burden of Alzheimer's disease. Alzheimers Dem 2007; 3: 186-191.
3. Ballard C, et al. Alzheimer's disease. Lancet 2011; 377: 1019-1031.
4. Ferri CP, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366: 2112-2117.
5. Kalaria RN, et al. Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors. Lancet Neurol 2008; 7: 812-826.
6. Portelius E, et al. An Alzheimer's disease-specific β-amyloid fragment signature in cerebrospinal fluid. Neurosci Lett 2006; 409: 215-219.
7. Kril JJ,. Alzheimer disease: Alzheimer disease neuropathology in the oldest old. Nat Rev Neurol 2009; 5: 411-412.
8. Schliebs R, Arendt T,. The significance of the cholinergic system in the brain during aging and in Alzheimer's disease. J Neural Transm 2006; 113: 1625-1644.
9. Sauvaitre T, et al. New potent acetylcholinesterase inhibitors in the tetracyclic triterpene series. J Med Chem 2007; 50: 5311-5323.
10. Lleo A, et al. Current pharmacotherapy for Alzheimer's disease. Annu Rev Med 2006; 57: 513-533.
11. Mangialasche F, et al. Alzheimer's disease: clinical trials and drug development. Lancet Neurol 2010; 9: 702-716.
12. Buckholtz NS,. Perspective: in search of biomarkers. Nature 2011; 475: S8.
13. Yamada K, Nabeshima T,. Animal models of Alzheimer's disease and evaluation of anti-dementia drugs. Pharmacol Ther 2000; 88: 93-113.
14. Van Dam D, De Deyn PP,. Animal models in the drug discovery pipeline for Alzheimer's disease. Br J Pharmacol 2011; 164: 1285-1300.
15. Mattson MP,. Pathways towards and away from Alzheimer's disease. Nature 2004; 430: 631-639.
16. Benson A,. Alzheimer's disease: a tangled issue. Drug Discov Today 2005; 10: 749-751.
17. Hardy J, Allsop D,. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 1991; 12: 383-388.
18. Wang YP, et al. Endogenous overproduction of β-amyloid induces tau hyperphosphorylation and decreases the solubility of tau in N2a cells. J Neural Transm 2006; 113: 1723-1732.
19. Conway KA, et al. Emerging beta-amyloid therapies for the treatment of Alzheimer's disease. Curr Pharm Des 2003; 9: 427-447.
20. Morgan C, et al. Structure and function of amyloid in Alzheimer's disease. Prog Neurobiol 2004; 74: 323-349.
21. Bekris LM, et al. Genetics of Alzheimer disease. J Geriatr Psychiatry Neurol 2010; 23: 213-227.
22. Hoyer S,. Memory function and brain glucose metabolism. Pharmacopsychiatry 2003; 36: S62-S67.
23. Sun XT, et al. Review of drugs for Alzheimer's disease. Drug Discov Ther 2012; 6: 285-290.
24. Squier TC,. Oxidative stress and protein aggregation during biological aging. Exp Gerontol 2001; 36: 1539-1550.
25. He H, et al. Anti-Amyloidogenic and anti-apoptotic role of melatonin in Alzheimer disease. Curr Neuropharmacol 2010; 8: 211-217.
26. Cummings JL,. Treatment of Alzheimer's disease: current and future therapeutic approaches. Rev Neurol Dis 2004; 1: 60-69.
27. Schliebs R,. Basal forebrain cholinergic dysfunction in Alzheimer's disease-interrelationship with beta-amyloid, inflammation and neurotrophin signaling. Neurochem Res 2005; 30: 895-908.
28. Churcher I,. Tau therapeutic strategies for the treatment of Alzheimer's disease. Curr Top Med Chem 2006; 6: 579-595.
29. Selkoe DJ,. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001; 81: 741-766.
30. Cummings JL,. The role of cholinergic agents in the management of behavioural disturbances in Alzheimer's disease. Int J Neuropsychopharmacol 2000; 3: S21-S29.
31. Lahiri DK, et al. Current drug targets for Alzheimer's disease treatment. Drug Dev Res 2002; 56: 267-281.
32. Giacobini E,. Cholinesterases: new roles in brain function and in Alzheimer's disease. Neurochem Res 2003; 28: 515-522.
33. Pakaski M, Kalman J,. Interactions between the amyloid and cholinergic mechanisms in Alzheimer's disease. Neurochem Int 2008; 53: 103-111.
34. Greenblatt HM, et al. The complex of a bivalent derivative of galanthamine with torpedo acetylcholinesterase displays drastic deformation of the active-site gorge: implications for structure-based drug design. J Am Chem Soc 2004; 126: 15405-15411.
35. Francis PT, et al. Neurochemical basis for symptomatic treatment of Alzheimer's disease. Neuropharmacology 2010; 59: 221-229.
36. Greig NH, et al. Butyrylcholinesterase: an important new target in Alzheimer's disease therapy. Int Psychogeriatr 2002; 14: 77-91.
37. Beard CM, et al. The prevalence of dementia is changing over time in Rochester, Minnesota. Neurology 1995; 45: 75-79.
38. Munoz-Torrero D,. Acetylcholinesterase inhibitors as disease-modifying therapies for Alzheimer's disease. Curr Med Chem 2008; 15: 2433-2455.
39. Ballard CG, et al. Cholinesterases: roles in the brain during health and disease. Curr Alzheimer Res 2005; 2: 307-318.
40. Loizzo MR, et al. Natural products and their derivatives as cholinesterase inhibitors in the treatment of neurodegenerative disorders: an update. Curr Med Chem 2008; 15: 1209-1228.
41. Martinez A, Castro A,. Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer's disease. Expert Opin Investig Drugs 2006; 15: 1-12.
42. Orhan IE, et al. An overview on natural cholinesterase inhibitors-a multi-targeted drug class-and their mass production. Mini-Rev Med Chem 2011; 11: 836-842.
43. Eagger SA, et al. Tacrine in Alzheimer's disease. Lancet 1991; 337: 989-992.
44. Schneider LS,. Clinical pharmacology of aminoacridines in Alzheimer's disease. Neurology 1993; 43: S64-S79.
45. Davis KL, Powchick P,. Tacrine. Lancet 1995; 345: 625-630.
46. Siddiqui MF, Levey AI,. Cholinergic therapies in Alzheimer's disease. Drugs Future 1999; 24: 417-424.
47. Geldmacher DS,. Donepezil (Aricept) for treatment of Alzheimer's disease and other dementing conditions. Expert Rev Neurother 2004; 4: 5-16.
48. Rogers SL, et al. E2020 produces both clinical global and cognitive test improvement in patients with mild to moderately severe Alzheimerr's diseases: results of 30-week phase III trial. Neurology 1996; 46: A217.
49. Scarpini E, et al. Treatment of Alzheimer's disease: current status and new perspectives. Lancet Neurol 2003; 2: 539-547.
50. Bores GM, et al. Pharmacological evaluation of novel Alzheimer's disease therapeutics: acetylcholinesterase inhibitors related to galanthamine. J Pharmacol Exp Ther 1996; 277: 728-738.
51. Harvey AL,. The pharmacology of galanthamine and its analogues. Pharmacol Ther 1995; 68: 113-128.
52. Wilkinson DG, et al. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy. Drugs Aging 2004; 21: 453-478.
53. Elgorashi EE, et al. Acetylcholinesterase enzyme inhibitory effects of Amaryllidaceae alkaloids. Planta Med 2004; 70: 260-262.
54. Tariot PN, Federoff HJ,. Current treatment for Alzheimer disease and future prospects. Alzheimer Dis Assoc Disord 2003; 17: S105-S113.
55. Perry EK, et al. Medicinal plants and Alzheimer's disease: from ethnobotany to phytotherapy. J Pharm Pharmacol 1999; 51: 527-534.
56. Hostettmann K, et al. Natural product inhibitors of acetylcholinesterase. Curr Org Chem 2006; 10: 825-847.
57. Houghton PJ, et al. Acetylcholinesterase inhibitors from plants and fungi. Nat Prod Rep 2006; 23: 181-199.
58. Mukherjee PK, et al. Acetylcholinesterase inhibitors from plants. Phytomedicine 2007; 14: 289-300.
59. Mukherjee PK, et al. Lead findinding for acetyl cholinesterase inhibitors from natural origin: structure activity relationship and scope. Mini Rev Med Chem 2011; 11: 247-262.
60. Orhan IE,. Current concepts on selected plant secondary metabolites with promising inhibitory effects against enzymes linked to Alzheimer's disease. Curr Med Chem 2012; 19: 2252-2261.
61. Pereira DM, et al. Pharmacological effects of Catharanthus roseus root alkaloids in acetylcholinesterase inhibition and cholinergic neurotransmission. Phytomedicine 2010; 17: 646-652.
62. Bruhlmann C, et al. Screening of non-alkaloidal natural compounds as acetylcholinesterase inhibitors. Chem Biodivers 2004; 1: 819-829.
63. Bruneton J,. Pharmacognosie Phytochimie Plantes Médicinale, 3ème edn. Paris: Tec & Doc Lavoisier, 1999.
64. Asthana S, et al. Treatment of Alzheimer disease by continuous intravenous infusion of physostigmine. Alzheimer Dis Assoc Disord 1995; 9: 223-232.
65. Thal LJ, et al. A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease. Physostigmine Study Group. Neurology 1996; 47: 1389-1395.
66. Guo B, et al. Research advances of Huperzia serrata (Thunb.) Trev. J Chin Mat Med 2009; 34: 2018-2023.
67. Ma X, et al. Huperzine A from Huperzia species-an ethnopharmacolgical review. J Ethnopharmacol 2007; 113: 15-34.
68. Zhang HY, Tang XC,. Neuroprotective effects of huperzine A: new therapeutic targets for neurodegenerative disease. Trends Pharmacol Sci 2006; 27: 619-625.
69. Liang YQ, Tang XC,. Comparative effects of huperzine A, donepezil and rivastigmine on cortical acetylcholine level and acetylcholinesterase activity in rats. Neurosci Lett 2004; 361: 56-59.
70. Xu SS, et al. Huperzine-A in capsules and tablets for treating patients with Alzheimer disease. Zhongguo Yao Li Xue Bao 1999; 20: 486-490.
71. Zhang Z, et al. Clinical efficacy and safety of huperzine Alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial. Zhonghua Yi Xue Za Zhi 2002; 82: 941-944.
72. Rafii MS, et al. A phase II trial of huperzine A in mild to moderate Alzheimer disease. Neurology 2011; 76: 1389-1394.
73. Ma X, Gang DR,. The Lycopodium alkaloids. Nat Prod Rep 2004; 21: 752-772.
74. Lopez S, et al. Acetylcholinesterase inhibitory activity of some Amaryllidaceae alkaloids and Narcissus extracts. Life Sci 2002; 71: 2521-2529.
75. Pagliosa LB, et al. Effect of isoquinoline alkaloids from two Hippeastrum species on in vitro acetylcholinesterase activity. Phytomedicine 2010; 17: 698-701.
76. Kim DK,. Inhibitory effect of corynoline isolated from the aerial parts of Corydalis incisa on the acetylcholinesterase. Arch Pharm Res 2002; 25: 817-819.
77. Kim DK, et al. Acetylcholinesterase inhibitors from the aerial parts of Corydalis speciosa. Arch Pharm Res 2004; 27: 1127-1131.
78. Rahman AU, Choudhary MI,. Bioactive natural products as a potential source of new pharmacophores. A theory of memory. Pure Appl Chem 2001; 73: 555-560.
79. Ortega MG, et al. Anticholinesterase activity in an alkaloid extract of Huperzia saururus. Phytomedicine 2004; 11: 539-543.
80. Konrath EL, et al. Investigation of the in vitro and ex vivo acetylcholinesterase and antioxidant activities of traditionally used Lycopodium species from South America on alkaloid extracts. J Ethnopharmacol 2012; 139: 58-67.
81. Konrath EL, et al. Alkaloid profiling and anticholinesterase activity of South American Lycopodiaceae species. J Enzyme Inhib Med Chem 2013; 28: 218-222.
82. Andrade MT, et al. Indole alkaloids from Tabernaemontana australis (Muell. Arg) Miers that inhibit acetylcholinesterase enzyme. Bioorg Med Chem 2005; 13: 4092-4095.
83. Rahman AU, et al. Diterpenoid and steroidal alkaloids. Nat Prod Rep 1997; 14: 191-203.
84. Khalid A, et al. Kinetics and structure-activity relationship studies on pregnane-type steroidal alkaloids that inhibit cholinesterases. Bioorg Med Chem 2004; 12: 1995-2003.
85. Rahman AU, et al. New pregnane-type steroidal alkaloids from Sarcocca saligna and their cholinesterase inhibitory activity. Steroids 2004; 69: 735-741.
86. Devkota KP, et al. Cholinesterase inhibiting and antiplasmodial steroidal alkaloids from Sarcococca hookeriana. Chem Pharm Bull 2007; 55: 1397-1401.
87. Kalauni SK, et al. New cholinesterase inhibiting steroidal alkaloids from the leaves of Sarcococca coriacea of Nepalese origin. Chem Pharm Bull 2002; 50: 1423-1426.
88. Choudhary MI, et al. Cholinesterase-inhibiting new steroidal alkaloids from Sarcococca hookeriana of Nepalese Origin. Helv Chim Acta 2004; 87: 1099-1108.
89. Choudhary MI, et al. Cholinesterase inhibitory pregnane-type steroidal alkaloids from Sarcococca hookeriana. Steroids 2005; 70: 295-303.
90. Devkota KP, et al. Bioactive 5α-Pregnane-Type Steroidal Alkaloids from Sarcococca hookeriana. J Nat Prod 2008; 71: 1481-1484.
91. Rahman AU, et al. New Cholinesterase-Inhibiting Steroidal Alkaloids from Sarcococca saligna. Helv Chim Acta 2004; 87: 439-448.
92. Khalid A, et al. Cholinesterase inhibitory and spasmolytic potential of steroidal alkaloids. J Steroid Biochem Mol Biol 2004; 92: 477-484.
93. Kalauni SK, et al. Steroidal alkaloids from the leaves of Sarcococca coriacea of Nepalese origin. J Nat Prod 2001; 64: 842-844.
94. Rahman AU, et al. Pregnane-type steroidal alkaloids of Sarcococca saligna: a new class of cholinesterase inhibitors. Helv Chim Acta 2002; 85: 678-688.
95. Giliani AU, et al. Presence of antispasmodic, antidiarrheal, antisecretory, calcium antagonist and acetylcholinesterase inhibitory steroidal alkaloids in Sarcococca saligna. Planta Med 2005; 71: 120-125.
96. Zaheer ul H, et al. 3D-QSAR studies on natural acetylcholinesterase inhibitors of Sarcococca saligna by comparative molecular field analysis (CoMFA). Bioorg Med Chem Lett 2003; 13: 4375-4380.
97. Zaheer-Ul-Haq ZU, et al. Molecular docking studies of natural cholinesterase-inhibiting steroidal alkaloids from Sarcococca saligna. J Med Chem 2003; 46: 5087-5090.
98. Musharraf SG, et al. Structure-fragmentation relationship and rapid dereplication of Buxus steroidal alkaloids by electrospray ionization-quadrupole time-of-flight mass spectrometry. Rapid Commun Mass Spectrom 2013; 27: 169-178.
99. Babar ZU, et al. New bioactive steroidal alkaloids from Buxus hyrcana. Steroids 2006; 71: 1045-1051.
100. Choudhary MI, et al. New triterpenoid alkaloid cholinesterase inhibitors from Buxus hyrcana. J Nat Prod 2003; 66: 739-742.
101. Rahman AU, et al. Acetyl and butyrylcholinesterase-inhibiting triterpenoid alkaloids from Buxus papillosa. Phytochemistry 2001; 58: 963-968.
102. Choudhary MI, et al. New cholinesterase-inhibiting triterpenoid alkaloids from Buxus hyrcana. Chem Biodivers 2006; 3: 1039-1052.
103. Ata A, et al. Triterpenoidal alkaloids from Buxus hyrcana and their enzyme inhibitory, anti-fungal and anti-leishmanial activities. Phytochemistry 2010; 71: 1780-1786.
104. Matochko WL, et al. Triterpenoidal alkaloids from Buxus natalensis and their acetylcholinesterase inhibitory activity. J Nat Prod 2010; 73: 1858-1862.
105. Khalid A, et al. Structural basis of acetylcholinesterase inhibition by triterpenoidal alkaloids. Biochem Biophys Res Commun 2005; 331: 1528-1532.
106. Orhan IE, et al. Selective cholinesterase inhibitors from Buxus sempervirens L. and their molecular docking studies. Curr Comp Aided Drug Des 2011; 7: 276-286.
107. Zhou JL, et al. Characterization and identification of steroidal alkaloids in Fritillaria species using liquid chromatography coupled with electrospray ionization quadrupole time-of-flight tandem mass spectrometry. J Chromatogr A 2010; 1217: 7109-7122.
108. Lin BQ, et al. Inhibitors of acetylcholine esterase in vitro-screening of steroidal alkaloids from Fritillaria species. Planta Med 2006; 72: 814-818.
109. Rahman AU, et al. New steroidal alkaloids from Fritillaria imperialis and their cholinesterase inhibiting activities. Chem Pharm Bull 2002; 50: 1013-1016.
110. Yang ZD, et al. Steroidal alkaloids from Holarrhena antidysenterica as acetylcholinesterase inhibitors and the investigation for structure-activity relationships. Life Sci 2012; 90: 929-933.
111. Halldorsdottir ES, et al. Acetylcholinesterase inhibitory activity of lycopodane-type alkaloids from the Icelandic Lycopodium annotinum ssp. alpestre. Phytochemistry 2010; 71: 149-157.
112. Koyama K, et al. Cryptadines A and B, novel C27N3-type pentacyclic alkaloids from Lycopodium cryptomerinum. Bioorg Med Chem 2007; 15: 7803-7808.
113. Hirasawa Y, et al. Lycoperine A, A novel C27N3-type pentacyclic alkaloid from Lycopodium hamiltonii, inhibiting acetylcholinesterase. Org Lett 2005; 8: 123-126.
114. Choo CY, et al. Carinatumins A-C, new alkaloids from Lycopodium carinatum inhibiting acetylcholinesterase. Bioorg Med Chem 2007; 15: 1703-1707.
115. Hirasawa Y, et al. Lycoparins A-C, new alkaloids from Lycopodium casuarinoides inhibiting acetylcholinesterase. Bioorg Med Chem 2008; 16: 6167-6171.
116. Hirasawa Y, et al. Sieboldine A, a novel tetracyclic alkaloid from Lycopodium sieboldii, inhibiting acetylcholinesterase. Org Lett 2003; 5: 3991-3993.
117. Konrath EL,. Química, atividades antioxidante e anticolinesterásicas de espécies da família Lycopodiaceae. PhD Thesis. Faculty of Pharmacy. Federal University of Rio Grande do Sul (UFRGS): Porto Alegre, 2011.
118. Ghosal S, et al. Crinum alkaloids: their chemistry and biology. Phytochemistry 1985; 24: 2141-2156.
119. Greenblatt HM, et al. Structure of acetylcholinesterase complexed with (-)-galanthamine at 2.3 A resolution. FEBS Lett 1999; 463: 321-326.
120. Reyes-Chilpa R, et al. Acetylcholinesterase-inhibiting alkaloids from Zephyranthes concolor. Molecules 2011; 16: 9520-9533.
121. Bartolucci C, et al. Three-dimensional structure of a complex of galanthamine (Nivalin) with acetylcholinesterase from Torpedo californica: implications for the design of new anti-Alzheimer drugs. Proteins 2001; 42: 182-191.
122. Rhee IK, et al. Isolation of the acetylcholinesterase inhibitor ungeremine from Nerine bowdenii by preparative HPLC coupled on-line to a flow assay system. Biol Pharm Bull 2004; 27: 1804-1809.
123. Sarikaya BB, et al. Alkaloids from Galanthus rizehensis. Phytochem Lett 2012; 5: 367-370.
124. Houghton PJ, et al. Choline esterase inhibitory properties of alkaloids from two Nigerian Crinum species. Phytochemistry 2004; 65: 2893-2896.
125. Adewusi EA, et al. Cytotoxicity and acetylcholinesterase inhibitory activity of an isolated crinine alkaloid from Boophane disticha (Amaryllidaceae). J Ethnopharmacol 2012; 143: 572-578.
126. Ingkaninan K, et al. Acetylcholinesterase inhibitors from Stephania venosa tuber. J Pharm Pharmacol 2006; 58: 695-700.
127. Huang QQ, et al. Bioactive isoquinoline alkaloids from Corydalis saxicola. Planta Med 2011; 78: 65-70.
128. Brunhofer G, et al. Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine. Bioorg Med Chem 2012; 20: 6669-6679.
129. Hung TM, et al. Cholinesterase inhibitory activities of alkaloids from Corydalis tuber. Nat Prod Sci 2011; 17: 108-112.
130. Hung TM, et al. Cholinesterase inhibitory and anti-amnesic activity of alkaloids from Corydalis turtschaninovii. J Ethnopharmacol 2008; 119: 74-80.
131. Hung TM, et al. Alkaloids from roots of Stephania rotunda and their cholinesterase inhibitory activity. Planta Med 2010; 76: 1762-1764.
132. Jung HA, et al. Anti-Alzheimer and antioxidant activities of Coptidis Rhizoma alkaloids. Biol Pharm Bull 2009; 32: 1433-1438.
133. Ji HF, Shen L,. Berberine: a potential multipotent natural product to combat Alzheimer's disease. Molecules 2011; 16: 6732-6740.
134. Ji HF, Shen L,. Molecular basis of inhibitory activities of berberine against pathogenic enzymes in Alzheimer's disease. Sci World J 2012; 2012: 823201.
135. Asai M, et al. Berberine alters the processing of Alzheimer's amyloid precursor protein to decrease Abeta secretion. Biochem Biophys Res Commun 2007; 352: 498-502.
136. Xiao HT, et al. Acetylcholinesterase inhibitors from Corydalis yanhusuo. Nat Prod Res 2011; 25: 1418-1422.
137. Tsai SF, Lee SS,. Characterization of acetylcholinesterase inhibitory constituents from Annona glabra assisted by HPLC microfractionation. J Nat Prod 2010; 73: 1632-1635.
138. Adsersen A, et al. Acetylcholinesterase and butyrylcholinesterase inhibitory compounds from Corydalis cava Schweigg. & Kort. J Ethnopharmacol 2007; 113: 179-182.
139. Mollataghi A, et al. Anti-acetylcholinesterase, anti-alpha-glucosidase, anti-leishmanial and anti-fungal activities of chemical constituents of Beilschmiedia species. Fitoterapia 2012; 83: 298-302.
140. Cometa MF, et al. New cholinesterase inhibiting bisbenzylisoquinoline alkaloids from Abuta grandifolia. Fitoterapia 2012; 83: 476-480.
141. Rahman AU, et al. New cholinesterase inhibiting bisbenzylisoquinoline alkaloids from Cocculus pendulus. Chem Pharm Bull 2004; 52: 802-806.
142. Passos CS, et al. Indole alkaloids of Psychotria as multifunctional cholinesterases and monoamine oxidases inhibitors. Phytochemistry 2013; 86: 8-20.
143. Bharate SB, et al. Total synthesis and anti-cholinesterase activity of marine-derived bis-indole alkaloid fascaplysin. MedChemComm 2012; 3: 1098-1103.
144. Geissler T, et al. Acetylcholinesterase inhibitors from the toadstool Cortinarius infractus. Bioorg Med Chem 2010; 18: 2173-2177.
145. Schott Y, et al. 6-Hydroxy- and 6-methoxy-beta-carbolines as acetyl- and butyrylcholinesterase inhibitors. Bioorg Med Chem Lett 2006; 16: 5840-5843.
146. Torres JM, et al. Structural insights into cholinesterases inhibition by harmane β-carbolinium derivatives: a kinetics-Molecular modeling approach. Phytochemistry 2012; 81: 24-30.
147. Becher PG, et al. Nostocarboline: isolation and synthesis of a new cholinesterase inhibitor from Nostoc 78-12A. J Nat Prod 2005; 68: 1793-1795.
148. Becher PG, et al. The cyanobacterial alkaloid nostocarboline: an inhibitor of acetylcholinesterase and trypsin. J Appl Phycol 2009; 21: 103-110.
149. Choudhary MI, et al. Juliflorine: a potent natural peripheral anionic-site-binding inhibitor of acetylcholinesterase with calcium-channel blocking potential, a leading candidate for Alzheimer's disease therapy. Biochem Biophys Res Commun 2005; 332: 1171-1177.
150. Ferheen S, et al. Haloxylines A and B, antifungal and cholinesterase inhibiting piperidine alkaloids from Haloxylon salicornicum. Chem Pharm Bull 2005; 53: 570-572.
151. Nukoolkarn VS, et al. Petrosamine, a potent anticholinesterase pyridoacridine alkaloid from a Thai marine sponge Petrosia n. sp. Bioorg Med Chem 2008; 16: 6560-6567.
152. Cardoso-Lopes EM, et al. Alkaloids from stems of Esenbeckia leiocarpa Engl. (Rutaceae) as potential treatment for Alzheimer disease. Molecules 2010; 15: 9205-9213.
153. Wang YH, et al. Benzylphenethylamine alkaloids from Hosta plantaginea with inhibitory activity against tobacco mosaic virus and acetylcholinesterase. J Nat Prod 2007; 70: 1458-1461.
154. Francis PT, et al. The cholinergic hipothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 1999; 66: 137-147.
155. Eriksson AH, et al. In vitro evaluation of the P-glycoprotein interactions of a series of potentially CNS active Amaryllidaceae alkaloids. J Pharm Pharmacol 2012; 64: 1667-1677.
156. McNulty J, et al. Selective cytochrome P450 3A4 inhibitory activity of Amaryllidaceae alkaloids. Bioorg Med Chem Lett 2009; 19: 3233-3237.